Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ophthalmology. 2014 Apr;121(4):905-10. doi: 10.1016/j.ophtha.2013.10.047. Epub 2013 Dec 21.

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.

Author information

  • 1Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany.
  • 2Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • 3Institute of Human Genetics, Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg, Germany.
  • 4Max Planck Institute for Neurological Research, Neuromodulation and Neurorehabilitation Group, Cologne, Germany; Department of Neurology, University Hospital of Cologne, Cologne, Germany.
  • 5Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • 6Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany. Electronic address: sascha.fauser@uk-koeln.de.

Abstract

PURPOSE:

Intravitreal anti-vascular endothelial growth factor (VEGF) injections are currently the standard treatment for neovascular age-related macular degeneration (AMD), but a broad range of response rates has been observed. We evaluated the association of single nucleotide polymorphisms (SNPs) in VEGF genes and their receptors (VEGFR) with the response rate to ranibizumab in 366 patients with neovascular AMD.

DESIGN:

Case series study.

PARTICIPANTS:

A total of 366 eyes of 366 patients with neovascular AMD.

METHODS:

Visual acuity (VA) was determined at baseline, after 3 monthly ranibizumab injections, and after 1 year of treatment. Genotyping of 126 SNPs in the genes encoding VEGF family members VEGFA, VEGFB, VEGFC, VEGFD (FIGF), and placental growth factor (PGF); VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4); and the gene encoding pigment epithelium-derived factor (PEDF) (SERPINF1) was performed.

MAIN OUTCOME MEASURES:

The changes in VA after 3 injections and after 1 year of treatment and their association with VEGF and VEGFR genotypes.

RESULTS:

Univariate analyses of variance (ANOVAs) revealed a significant effect of SNP rs4576072 in the VEGFR2 gene on VA change after 12 months (F[1,235] = 14.05; P = 0.02). A stepwise linear regression analysis returned a model (P = 0.01) with SNPs rs4576072 and rs6828477 in the VEGFR2 gene as independent predictors for VA change after 12 months, with a mean increase in VA of 0.26 on the logarithm of the minimum angle of resolution (logMAR) scale in patients with 3 contributing minor alleles compared with a loss of 0.03 logMAR in patients with no minor allele.

CONCLUSIONS:

Polymorphisms in the VEGFR2/KDR gene significantly influence visual outcome in patients receiving ranibizumab treatment for neovascular AMD. This study shows that genetic variation partially explains the wide range of response to ranibizumab treatment, which in the future might help clinicians tailoring medical interventions to individual needs.

Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

PMID:
24365177
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk